Eli Lilly shared additional safety and tolerability data on its next-generation obesity drug retatrutide, highlighting arrhythmia and major cardiovascular event rates in a late-stage dataset. The updates were presented at the American Diabetes Association meeting and published in The Lancet. In the new disclosure, arrhythmias occurred in 7 of 403 retatrutide-treated participants, while major cardiovascular complications affected 3 participants versus none on placebo. The company’s earlier reports emphasized rapid weight loss, but the incremental detail shifts attention to risk management. The development lands as obesity programs face tighter payer and regulator expectations for benefit-risk profiles, especially for drugs with cardiovascular signals to monitor over longer exposures.